Tudor Investment Corporation »

Crinetics Pharmaceuticals In shares owned by Tudor Investment Corporation

Quarter-by-quarter ownership of Crinetics Pharmaceuticals In (CRNX) shares owned by Tudor Investment Corporation from 13F filings

Historical chart of Tudor Investment Corporation investment in Crinetics Pharmaceuticals In

Tip: Access up to 7 years of quarterly data

All positions including Crinetics Pharmaceuticals In held by Tudor Investment Corporation consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crinetics Pharmaceuticals In by Tudor Investment Corporation

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.4M 40k 35.58
2023-09-30 $981k 33k 29.74
2023-06-30 $487k 27k 18.02
2022-09-30 $525k 27k 19.62

More positions owned by Tudor Investment Corporation

Ishares Russell 2000 Etf - US ETP ETF Option Call Option (IWM)
Splunk Inc - US Equity
Pioneer Natural Resources Co - US Equity (PXD)
Financial Select Sector Spdr Fund - US ETP ETF Option Call Option (XLF)
Ishares Msci Emerging Markets Etf - US ETP ETF Option Call Option (EEM)
Spdr Dow Jones Industrial Average Etf Trust - US E ETF Option Call Option (DIA)
Exxon Mobil Corp - US Equity (XOM)
Meta Platforms Inc - US Equity (META)
Bristol-Myers Squibb Co - US Equity (BMY)
Texas Instruments Inc - US Equity Option Call Option (TXN)
Enphase Energy Inc - US Equity Option Call Option (ENPH)
United Parcel Service Inc - US Class B Equity Option Call Option (UPS)
Nvidia Corp - US Equity (NVDA)
Bank Of America Corp - US Equity (BAC)
Estee Lauder Cos Inc/The - US Equity (EL)

View all positions for Tudor Investment Corporation

Top funds holding Crinetics Pharmaceuticals In

Vanguard Group
Point72 Asset Management
Wellington Management Company
T. Rowe Price Associates
Jennison Associates
Paradigm Biocapital Advisors
EcoR1 Capital
First Light Asset Management
OrbiMed Advisors
Perceptive Advisors
Cormorant Asset Management
Eventide Asset Management
Lord, Abbett & Co
Ikarian Capital
Goldman Sachs Group

View all funds holding Crinetics Pharmaceuticals In